Exploring Immunotherapy in Patients With Esophageal Cancer

Manish A. Shah, MD, director of Gastrointestinal Oncology at Weill Cornell Medicine, discusses the need for targeted therapies beyond the second-line setting in esophageal cancer. While this is a deadly disease with most metastatic patients dying within a year, a recent clinical trial with pembrolizumab (Keytruda) addresses an unmet need in the population, Shah says.


Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *